An interventional study of exrecise intervention in Prostate Cancer, sponsored by Duke University. Completed at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-08-26.
Sponsored by Duke University · Not applicable, Interventional, and Supportive care
Among 49 studies in Prostatic Neoplasms by Duke University — 4 open to participants now, 5 under way, none of them phase 3. Prostatic Neoplasms · Duke University.
Among the 49 studies in Prostatic Neoplasms by Duke University, this one is the 26th largest by enrollment of the 34 interventional ones that give a count, is one of 2 that started in 2018, is one of 18 with no phase, and was the 37th registered.
7,046 studies on the registry are indexed under Prostatic Neoplasms; 1,580 are open to participants now.
Browse Prostatic Neoplasms studies →4 of the 49 studies in Prostatic Neoplasms by Duke University are open now, in 1 country. Recruiting first, the newest first:
Duke University · Sites in United States
Duke University · Sites in United States
Duke University · Sites in United States
Duke University · Sites in United States
By country, each count listing its studies:
Of the 1,228 Prostatic Neoplasms studies recruiting now, 928 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 14
First in 1988; this study’s year is marked. 2 started in 2018.
This study's enrollment of 13 is below the median of 60 across 5,348 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 35 across the 34 interventional studies, 120 across the 13 observational. Of the 41 that completed or were terminated, 12 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
Duke University is the lead sponsor of 2,063 studies on the registry; 273 are open to participants now.
Of its 204 completed or terminated interventional studies of FDA-regulated products, 167 (82%) have results posted.
3 of the studies in Prostatic Neoplasms by Duke University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06141993Duke UniversityARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials | 2027-04 |
| NCT07050433Duke UniversityCOMPASS Study for Metastatic Castration-resistant Prostate Cancer | 2027-07-01 |
| NCT07144228Duke UniversityValidation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer | 2027-09-30 |
Among the 49 studies in Prostatic Neoplasms by Duke University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Recent research has indicated that physical activities incorporating moderate-intensity exercise can be safely performed during treatment and substantially reduces treatment-related side effects, such as fatigue, sleep disturbances, cognitive impairment, and nausea. However, little is known about physical activity levels prior to treatment and whether providing an exercise intervention pre-treatment may improve functional capacity during treatment.
The purpose of this study is to
Explore whether a 2-week physical activity intervention is feasible during the pre-treatment timeframe:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Behavioral: exrecise intervention
Subjects will undergo pre-intervention measures, complete a daily physical activity diary, and post-intervention measures
Change in 6 minute walk test
Distance walked in 6 minutes
Time frame: baseline, 2 weeks post intervention
Change in balance test
Ability to balance
Time frame: baseline, 2 weeks post intervention
Change in time up to go test
Time to get up from chair, walk 30 meters and return to sit in chair
Time frame: baseline, 2 weeks post intervention
Change in Godin Leisure Time Score
physical activity score
Time frame: baseline, 2 weeks post intervention
Change in rate of perceived exertion
physical exertion score
Time frame: baseline, 2 weeks post intervention
Change in metabolic equivalent
metabolic activity score
Time frame: baseline, 2 weeks post intervention
Change in distress score
distress score
Time frame: baseline, 2 weeks post intervention
Change in self-efficacy score
self-efficacy score
Time frame: baseline, 2 weeks post intervention
Change in symptom inventory score
description of symptoms
Time frame: baseline, 2 weeks post intervention
Plan to share: No — No plan to share feasibility study data
No publications or documents are linked to this record.
Ran from Apr 2018 to primary completion in Mar 2019, 11 months.
Of 1,098 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 86. This study's 11 months is below that.
Counting every sponsor, half of 1,155 studies reached it within 43 months; a quarter within 22 and three quarters within 84.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.